CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The purpose of this study is to test whether giving acalabrutinib is safe and effective in controlling relapsed central nervous system (CNS) lymphoma...
Phase 2
Tampa, Florida, United States and 2 other locations
The purpose of the study is to establish the safety and efficacy of zanubrutinib in combination with rituximab for people with untreated B-cell lymphomas...
Phase 2
Tampa, Florida, United States
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...
Phase 1, Phase 2
Tampa, Florida, United States and 68 other locations
to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma...
Phase 2
Tampa, Florida, United States and 56 other locations
maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma...
Phase 2
Tampa, Florida, United States and 39 other locations
of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients with advanced solid tumors and lymphomas...
Phase 1, Phase 2
Tampa, Florida, United States and 81 other locations
by the intravenous (IV) route to participants with solid tumors or lymphomas.The main goals of this study are to:* Find the recommended dose...
Phase 1, Phase 2
Sarasota, Florida, United States and 8 other locations
of this study is to characterize the safety and efficacy profile of ACP-196 (acalabrutinib) in subjects with relapsed or refractory Mantle Cell Lymphoma...
Phase 2
Tampa, Florida, United States and 57 other locations
The purpose of this trial is to measure the following in participants with relapsed and/or refractory B-cell lymphoma who receive epcoritama...
Phase 1, Phase 2
Tampa, Florida, United States and 84 other locations
This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or...
Phase 1
Tampa, Florida, United States and 13 other locations
Clinical trials
Research sites
Resources
Legal